Fertility in Healthy Premenopausal Women
Fertility in Healthy Premenopausal Women
The study objectives are described below:

 1. Obtain serum specimens collected for one ovulatory cycle or a maximum of 33 days, but
 not to exceed a total of 550 ml of whole blood per subject from a minimum of 60 healthy,
 premenopausal subjects. Specimens will be used to determine a reference range for
 estradiol, FSH, LH, and progesterone assays, used as an aid in the assessment of
 fertility in adult, premenopausal women.

 2. To store any remaining specimens for use in future assay development and to evaluate as
 yet undetermined assays for the development of IVDs, including additional estradiol,
 FSH, LH, and progesterone assays.
The purpose of this study is to obtain sufficient specimens and correlating clinical data
 from a well-controlled prospective clinical trial collecting specimens from healthy,
 premenopausal subjects to support domestic and international regulatory submissions on
 fertility biomarker assays, and to establish a collection of specimens that will support
 future assay discovery and validation efforts.
Inclusion Criteria:

 -  Females, age ≥ 21 years

 -  Premenopausal (defined as a woman that has had at least one menstrual cycle in the
 last 365 days).

 -  A minimum weight of 110 lbs

 -  The subject is not anemic (Hemoglobin ≥ 12.5 g/dL)

 -  Willing to provide a daily blood draw for one ovulatory cycle or a maximum of 33 days

 -  Able to understand and willing to provide informed consent.

 Exclusion Criteria:

 -  Males

 -  Females, age <21 years

 -  Weighing < 110 lbs

 -  Anemic (Hemoglobin < 12.5 g/dL)

 -  History of bilateral oophorectomy

 -  Females taking any form of hormonal birth control including:

 -  Oral contraceptive pill (combined or progestin-only) within five days enrollment.

 -  Contraceptive patch (such as Ortho Evra®) within seven days of enrollment.

 -  Vaginal contraceptive ring (such as NuvaRing™) within 21 days of enrollment.

 -  Contraceptive injection (such as Depo-Provera®) within 90 days of enrollment.

 -  Intra-uterine system (IUS) within 90 days of enrollment. An intra-uterine device
 (IUD) made of copper does not exclude the patient from participating in this
 study.

 -  Subdermal contraceptive implants (such as Nexplanon®) within 90 days of
 enrollment.

 -  Emergency contraceptive within 30 days of enrollment.

 -  Women in menopause (defined as the end of menstrual cycles or at least more than 365
 days since the last menstrual cycle)

 -  Amenorrhea except for women that continue to ovulate as documented in a physician note
 available to the enrolling center.

 -  Has a current diagnosis of any clinically significant cardiac, respiratory,
 neurological, immunological, hematological, liver disease, renal disease,
 gastrointestinal (GI) disorder, including any history of hyper- or hypothyroid, peptic
 or gastric ulcers or GI bleeding, or any other condition which, in the opinion of the
 investigator, would deem the subject unhealthy and therefore, ineligible.

 -  Has a history of any clinically significant cardiac, respiratory, neurological,
 immunological, hematological, liver disease, renal disease, gastrointestinal (GI)
 disorder, including any history of hyper- or hypothyroid, peptic or gastric ulcers or
 GI bleeding, or any other condition which, in the opinion of the investigator, is
 unstable at the time of enrollment.

 -  Is receiving systemic chemotherapy or radiation treatment, has an active malignancy of
 any type, or has been diagnosed with cancer within 5 years before screening other than
 basal or squamous cell skin cancers or in-situ cervical cancer.

 -  History of seizures

 -  Diagnosed with an infectious disease including any sexually transmitted diseases.

 -  Diagnosed with HIV/AIDS or ever tested positive for HIV.

 -  History of hepatitis

 -  Subject that has had sexual contact with a person who has hepatitis within the last 12
 months.

 -  Pregnancy, lactation or actively seeking to conceive (trying to become pregnant).

 -  Unable to provide informed consent.